Financials in USD. Standardized financial statements.
A compact view of how Navidea Biopharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $65,652 | $531,513 | $915,013 | $26,618 | $322,521 | $1.81M | $21.97M | $13.25M | $6.27M | $1.13M |
| Revenue Growth? | -87.6% | -41.9% | +3337.6% | -91.7% | -82.2% | -91.8% | +65.8% | +111.1% | +455.0% | 0.0% |
| Cost of Revenue? | $184,947 | $198,834 | $1,048 | $6,667 | $96,636 | $3,651 | $2.30M | $1.75M | $1.59M | $332,815 |
| Gross Profit? | -$170,302 | $332,679 | $913,965 | $19,951 | $225,885 | $1.81M | $19.67M | $11.49M | $4.69M | $797,815 |
| Gross Margin? | -259.4% | +62.6% | +99.9% | +75.0% | +70.0% | +99.8% | +89.5% | +86.8% | +74.7% | +70.6% |
| Operating Expenses? | $13.88M | $12.39M | $11.63M | $10.98M | $11.07M | $15.68M | $21.90M | $30.05M | $32.32M | $39.24M |
| Operating Income? | -$14.05M | -$12.06M | -$10.71M | -$10.96M | -$10.85M | -$13.88M | -$2.22M | -$18.55M | -$27.63M | -$38.44M |
| EBITDA? | -$13.98M | -$11.51M | -$10.64M | -$10.82M | -$10.85M | -$13.14M | -$6.87M | -$21.31M | -$31.52M | -$38.03M |
| Income Before Tax | -$15.18M | -$11.71M | -$10.72M | -$10.94M | -$16.17M | -$17.79M | -$14.31M | -$28.76M | -$35.73M | -$42.70M |
| Income Tax Expense | $0 | $16,043 | $0 | $707 | $2,747 | -$4.06M | -$648,000 | -$436,051 | $2.68M | $0 |
| Net Income? | -$15.18M | -$11.73M | -$10.72M | -$10.95M | -$16.13M | $74.95M | -$14.31M | -$27.56M | -$35.73M | -$42.70M |
| EPS? | $-0.59 | $-0.40 | $-0.48 | $-0.76 | $-1.89 | $9.40 | $-1.84 | $-3.65 | $-4.80 | $-7.01 |
| Diluted EPS? | $-0.56 | $-0.40 | $-0.48 | $-0.76 | $-1.89 | $9.00 | $-1.84 | $-3.65 | $-4.80 | $-7.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality